Trial Information
Blood Samples to Evaluate Immune Response to Provenge® (Sipuleucel-T) inHormone Refractory Metastatic Prostate Cancer Patients
Inclusion Criteria
In order for patients to receive treatment with Provenge® (Sipuleucel-T) at the Mary
Crowley clinic, patients must consent to the additional blood draws and be willing to come
into the clinic in adherence to the schedule of blood sample collections. Patients who do
not consent to these immune response blood samples will be unable to receive Provenge®
(Sipuleucel-T) at Mary Crowley but will be referred to a another physician and/or clinic
able to provide Provenge® (Sipuleucel-T).
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Authority:
United States: Mary Crowley Medical Research Center IRB
Study ID:
MC 10-11
NCT ID:
NCT01274572
Start Date:
January 2011
Completion Date:
Related Keywords:
- Prostate Cancer
- Immune Response to Provenge
- Prostatic Neoplasms